ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
After today’s completion of the acquisition of Actelion Ltd by J&J for US$30bn in cash, equivalent to US$280 per share, through the US company’s Swiss subsidiary, Janssen Holding GmbH, Actelion will become part of Janssen Pharmaceuticals.
Boehringer Ingelheim has presented detailed pivotal double-blinded Phase III data, which prove comparability of its biosimilar candidate BI695501 to Humira in patients with moderate to severe Rheumatoid Arthritis.
Novartis and Alphabet/Google asset Verily Life Sciences LLC has co-invested into the late stage fund designed to finance programmes with up to €25m post clinical proof of concept.
Germany’s Constitutional Court has stopped the government from ratifying the EU’s Unitary Patent Package. At the time of the announcement, The German Bundestag and Council of Federal states had already adopted and signed the legislation.
French virology company Abivac will receive €390,000 for the development of a polyclonal antibody cocktail to fight Ebola.
Orphan diseases diagnostics specialist Centogene AG said it will use the funds for biomarker and CDx development based on its proprietary CentoMD mutation database.
Swedish orthobiologics company Bonesupport Holding AB announced on Sunday it will go public at Nasdaq Stockholm.
Norwegian cancer med developer Targovax ASA has doubled its cash and cash equivalents as of 31 December 2016 by raising NOK200m (€21m) in a private placement of new shares.
German Grünenthal Group has entered into an agreement to acquire the global rights to AstraZeneca’s migraine treatment Zolmitriptan.
Belgian liquid biopsy specialist Biocartis Group NV has announced it will co-develop a breast cancer assay with MRC Technology.